Clinical Trial Update: MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. [Phase 1]

View source ↗

Summary

Phase 1 study of MDN-001 Injection for unresectable primary hepatocellular carcinoma is currently recruiting. The sponsor is Suzhou Mednovo Yi Medical Technolog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• MDN-001 Injection

Snippet

Sponsor: Suzhou Mednovo Yi Medical Technology Co., Ltd. | Conditions: Hepatoma, Unresectable Hepatocellular Carcinoma (HCC) | Phase 1 | Status: RECRUITING